SG Americas Securities, LLC has opened a new $98.5M position in $BIIB, per a new SEC 13F filing. This disclosure reflects the funds' holdings for the 03-31-2025 ...

Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Earnings Yield Investor model based on the published strategy of ...

Biogen Inc. (BIIB) shares rallied 5.7% in the last trading ... estimate revisions are strongly correlated with near-term stock price movements. For Biogen, the consensus EPS estimate for the ...

Biogen Inc. (NASDAQ:BIIB – Get Free Report) has been given a consensus rating of “Hold” by the thirty-one brokerages that are ...

The firm decreased its portfolio allocation in BIIB by 18.27% over the last quarter ... the author and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of financial ...

In trading on Friday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 27.8, after changing hands as low as $123.02 per share. By comparison ...

The stock is flat since reporting and currently trades at $464.80. Founded in 1978 and pioneering treatments for some of ...

Shares of NASDAQ BIIB opened at $122.98 on Friday. The company has a 50 day simple moving average of $140.68 and a 200 day simple moving average of $157.62. The company has a debt-to-equity ratio ...

During the last three months, 14 analysts shared their evaluations of Biogen (NASDAQ:BIIB), revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of their ...

Jefferies analyst Michael Yee maintained a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $130.00. The ...

O Shaughnessy Asset Management LLC trimmed its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 53.6% during the 4th quarter, according to the company in its most recent Form 13F filing ...

TOKYO and CAMBRIDGE, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB ...